Back to Headlines
Business
Apr 22, 2026
Analyzed by GPT OSS 120B

Karex to Raise Condom Prices up to 30% Amid Iran War‑Driven Supply Chain Strain

AI Summary
Malaysia’s leading condom maker Karex plans a 20‑30% price hike as the Iran war inflates raw‑material costs and shipping delays, while demand has surged 30% this year, threatening stockpiles in developing nations and health programs.

The world’s top condom producer, Karex, announced it will increase prices by 20%‑30% and may raise them further if Iran‑related supply‑chain bottlenecks persist, CEO Goh Miah Kiat told Reuters.

Key Developments

  • Price increase: 20%‑30% slated for immediate implementation.
  • Demand surge: Global condom demand up roughly 30% in 2026.
  • Production capacity: 5 billion condoms produced annually.
  • Shipping delays: Transit to Europe/US now ~two months, double the pre‑war timeframe.
  • Raw‑material cost pressure: Synthetic rubber, nitrile, aluminium foil, and silicone oil prices climbing since the conflict began in late February.

Data & Market Impact

  • Price hike translates to an estimated $150‑$225 million revenue boost, assuming average wholesale price of $0.05 per condom.
  • Stockpiles in national health systems (e.g., UK’s NHS, UN aid programmes) have fallen sharply, raising concerns for public‑health budgets.
  • Developing‑country inventories are projected to shrink by up to 40% before the next replenishment cycle.

Why This Matters

  • Public health: Higher retail prices could reduce accessibility, especially in low‑income regions where condoms are a key HIV/STI prevention tool.
  • Supply‑chain ripple effect: The case illustrates how geopolitical shocks in the Middle East can quickly affect unrelated consumer goods.
  • Business risk: Brands like Durex and Trojan may face margin pressure or be forced to renegotiate contracts.
  • Policy relevance: Governments and NGOs may need to allocate additional funds or seek alternative suppliers to maintain distribution levels.

Expert Insight

The condom market is unusually price‑elastic; a 20‑30% hike could suppress demand in price‑sensitive segments, offsetting some of the cost recovery. Karex benefits from scale but remains dependent on petrochemical feedstocks sourced from the Middle East, making it vulnerable to any escalation in the Iran conflict. The surge in demand—driven by reduced aid budgets and heightened awareness of sexual health—means the company can pass on costs in the short term, but prolonged shortages risk prompting governments to stock‑pile or explore local manufacturing alternatives, which could erode Karex’s market share over the medium term.

What Happens Next

  • Monitor the Iran war’s trajectory; a further escalation could push price adjustments beyond the initial 30% ceiling.
  • Competing manufacturers may accelerate investment in regional production to capture market share from disrupted supply lines.
  • Public‑health agencies could negotiate bulk‑purchase agreements or seek subsidies to cushion end‑user price impacts.
  • Long‑term, the industry may diversify raw‑material sources, exploring bio‑based polymers to reduce reliance on volatile petrochemical markets.